Description

This issue of Vital Signs, released on October 18, 2010, provides a strategic overview of key issues and trends relating to advances in biopharmaceutical drug delivery. Additionally, a company spotlight is provided for QRxPharma Ltd., a clinical stage specialty pharmaceutical company focused on the development and commercialization of new therapies for CNS disorders and the management of pain. Reimbursement and regulatory news from the FDA is also provided for the week of September 27, 2010.